Abstract】Objective To observe the efficacy and safety of 0.1% sodium glassate drops (SH) and basic fibroblast growth factor (bFGF) drops in simple dry eyes and after excimer laser in situ keratomileusis (LASIK), respectively. Design Randomized controlled study. Subjects Seventy patients with simple dry eye (group I) and 40 patients (group II) who underwent LASIK at our ophthalmology outpatient clinic from January 2012 to August 2012. Methods Using a randomized, parallel controlled trial, Group I and Group II were each divided into two subgroups, and 0.1% SH eye drops (Group A) and bFGF eye drops (Group B) were administered 4 times daily using the random number method, with Group I being used topically for 14 consecutive days and Group II for 30 consecutive days. The patients were observed for changes in symptoms and signs at different time points (before, 7 and 14 days of administration in group I, and before, 1, 3, 10 and 30 days after surgery in group II). Questionnaires were used to investigate patients’ dry eye symptoms at different time points before and after medication, including easy fatigue, foreign body sensation, dryness, burning sensation, eye swelling, eye pain, photophobia and eye redness, which were rated from 0 to 9 according to the severity of patients’ self-conscious symptoms; three tests for tear quality and secretion, including tear film rupture time measurement (BUT), tear secretion test (SchirmerTestⅠ), and fluorescein staining ( FL). Main indicators Dry eye symptom score, BUT, Schirmer TestⅠ and FL, patient’s symptom self-evaluation. Results The results are written too confusingly, please revise: describe the symptoms, BUT, Schirmer, and FL comparisons in order, respectively, to be described by numbers, not simply by improvement, and specific P values written. Dry eye symptoms were significantly improved in the dry eye alone group (group I) after treatment, and the improvement of easy fatigue (p=0.006) and eye pain (p=0.040) 14 days after treatment was better in group IA than in group IB, and the difference was statistically significant. The patients with significant change in symptoms were 94.3% and 78.6% in IA and IB, respectively. BUT (p=0.055) and Schirmer Test I (p=0.573) improved IA more than IB, and FL (p=0.375) reduced IB better than IA, and the difference was not statistically significant. in the post-LASIK group (group II), patients showed more symptoms 1 and 3 days after surgery than before surgery discomfort symptoms, and all symptoms improved significantly 30 days after surgery, including foreign body sensation (p=0.004), burning sensation (p<0.001< font="">), eye swelling (p=0.005), and eye redness (p=0.007) improvement scores Group IIA was better than Group IIB. At 10 days postoperatively, BUT and Schirmer TestⅠ decreased and FL increased compared with preoperative, and all signs improved at 30 days postoperatively compared with 10 days postoperatively (BUT in group IIA: p=0.142, Schirmer TestⅠ: p=0.053, FL: p=0.005; BUT in group IIB: p=0.006, Schirmer TestⅠ: p=0.010, FL: p=0.079), and the improvement of all signs in group IIA compared with group IIB was not statistically significant (BUT: p=0.251, SchirmerTestⅠ: p=0.369, FL: p=0.060). The test of visual acuity was not mentioned in the method and appeared in the results, whether it is significant or not, both should be harmonized. No side effects were seen in all patients with the drug. Conclusion Both SH and bFGF eye drops promote corneal epithelial repair after simple dry eye and LASIK, maintain tear film stability, reduce symptoms such as easy fatigue, foreign body sensation, dryness, burning sensation, eye distention, eye pain, photophobia and eye redness, and have good compliance and are safe and effective. SH eye drops are superior to bFGF eye drops. [Keywords] Sodium vitrate; basic fibroblast growth factor; dry eye; excimer laser in situ keratomileusis